Who are Lozol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Catechin, Zaroxolyn, Combipres, CHLORTHALIDONE, Metolazone Tablets, IV Furosemide and PO Metolazone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/indapamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Lozol — Competitive Intelligence Brief

Lozol (INDAPAMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazide-like Diuretic [EPC]. Area: Immunology.

marketed Thiazide-like Diuretic [EPC] Carbonic anhydrase 7 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Lozol (INDAPAMIDE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lozol TARGET	INDAPAMIDE		marketed	Thiazide-like Diuretic [EPC]	Carbonic anhydrase 7	1983-01-01
Catechin	CIANIDANOL		marketed		Carbonic anhydrase 7	1977-01-01
Zaroxolyn	METOLAZONE	I3 Pharms	marketed	Thiazide-like Diuretic [EPC]	Carbonic anhydrase 7	1973-01-01
Combipres	Chlortalidone	University Hospital Birmingham	marketed	Thiazide-like Diuretic	Carbonic anhydrase 7	1960-01-01
CHLORTHALIDONE	CHLORTHALIDONE		marketed	Thiazide-like Diuretic [EPC]	Na+/Cl− cotransporter	1960-01-01
Metolazone Tablets	Metolazone Tablets	NHS Greater Glasgow and Clyde	marketed	Thiazide-like diuretic	Na-Cl cotransporter (NCC)
IV Furosemide and PO Metolazone	IV Furosemide and PO Metolazone	Rambam Health Care Campus	marketed	Loop diuretic and thiazide-like diuretic combination	Na-K-2Cl cotransporter (NKCC2) and Na-Cl cotransporter (NCC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-26 — Combipres · 9066936 · US
2030-02-04 — Combipres · 9169238 · US
2031-07-01 — Combipres · 9387249 · US

Sponsor landscape (Thiazide-like Diuretic [EPC] class)

· 2 drugs in this class
I3 Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lozol — Competitive Intelligence Brief. https://druglandscape.com/ci/indapamide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab